Shareholder advocacy

Aug. 2023 Dialogue with AEP on greenhouse gas targets and climate-related disclosures, climate lobbying, energy efficiency, Just Transition, renewable energy and capital expenditure plans.
Nov. 2022 Took part in an update and analysis on AEP’s Just Transition framework. Also reviewed AEP’s latest climate lobbying report.

March 2023 Dialogue on climate change including CapEx alignment versus climate scenarios, end use of products (Scope 3 emissions), climate lobbying and trade associations, and board oversight of climate strategy.
Nov. 2022 Dialogue with ConocoPhillips on climate change including the company’s climate alignment with its capital expenditures, Scope 3 emissions targets, climate lobbying and trade associations, and board oversight of climate strategy.

Sept. 2023 Dialogue on climate change, covering Net Zero carbon commitments, greening the company’s lending portfolio, and renewable energy financing.

Sept. 2023 Dialogue on climate change, covering Net Zero carbon commitments, greening the company’s lending portfolio, and renewable energy financing.
Dec. 2022 Co-filed shareholder proposal at Morgan Stanley asking the company to issue a report disclosing a climate transition plan that describes how it intends to align its financing activities with its 2030 sectoral greenhouse gas emissions reduction targets.

 Aug. 2023 Joined investor letter encouraging ISS to strengthen its benchmark policy on climate, as well as develop specialty policies that would provide a gold-standard approach to comprehensive climate voting recommendations and issuer analysis.

Jan. 2023 Dialogue with McDonald’s on ground for withdrawal of our shareholder proposal. The proposal requests that the company adopt an enterprise-wide policy to phase out the use of medically important antibiotics in its beef and pork supply chains.
Dec. 2022 Co-filed shareholder proposal at McDonald’s requesting that it adopt an enterprise-wide policy to phase out the use of medically-important antibiotics for disease prevention purposes in its beef and pork supply chains.
Nov. 2022 Dialogue with McDonald’s on antibiotics. We discussed topics including defining “responsible use”, antibiotic reduction targets, and fulfilment of the company’s 2020 goals.

March 2023 Dialogue with BRF on biodiversity, waste, and pollution risks and opportunities in its agricultural practices.

July 2023 Dialogue to discuss the company’s ongoing efforts to address human trafficking, including employee training, victims’ services, and coordination with law enforcement.
July 2022 Dialogue with Delta following-up on our June conversation. Discussed the company’s efforts to address human trafficking, its ongoing response to the COVID pandemic, as well as its efforts to support workers’ overall health and well-being.

Sept. 2023 Co-filed shareholder proposal requesting that Apple publish a report by March 2025 that assesses the risks of its products and services being used to facilitate online sexual exploitation of children, and the company’s efforts to prevent this activity.
Feb. 2023 Joined investor letter to Apple requesting that they improve their response to child safety risks and asking for a dialogue on the subject.

Feb. 2023 Dialogue with AT&T on prevention and action regarding online child exploitation. Conversation focused on measures companies are taking to protect children, metrics companies can report on this subject, and partnerships with law enforcement, NGOs, and industry peers.
Jan. 2022 Dialogue with AT&T on its efforts to combat child sexual exploitation online. Conversation focused on its child rights risk assessment, governance and oversight, employee training, and partnerships and collaborations.

Sept. 2023 Dialogue on their mining operations and relations with workers and indigenous tribes.

March 2023 Dialogue on indigenous rights with ConocoPhillips focusing on indigenous communities in Alaska’s North Slope, the Willow Project, and the process for gaining consent for development from communities.
Aug. 2022 Joined letter from the Gwich'in Steering Committee to leading insurance companies asking them not to insure drilling efforts in the Artic Refuge to respect the rights of Alaska Indigenous communities, and avoid harming wildlife and exacerbating climate change.

Sept. 2023 Joined investor letter asking the company to pay outstanding wage payments for garment workers in factories in Cambodia and Thailand employed by the Ramatex Group. Workers were dismissed and/or did not receive legally owed partial wages during a factory shutdown.

Sept. 2023 Signed on to investor letter requesting a meeting to discuss how the company is implementing the worker health and safety audit shareholder proposal and to share investor recommendations for the audit and reporting process.

Feb. 2023 Joined investor statement regarding the European Commission’s proposed legislation governing artificial intelligence (AI). While AI can enable advancements in some areas, it can contribute towards harms such as wide-spread surveillance, invasion of privacy and discrimination against the most vulnerable.

Jan. 2023 Signed on to investor statement supporting robust forced labor regulations and welcoming the European Commission’s proposal to prohibit products made with forced labor from entering the European Union market.

March 2023 Joined investor statement in support of ending the subminimum wage;. A “subminimum wage” is a wage paid that is less than the federal or state mandated minimum wage, which federal law allows with certain groups of workers. The subminimum wage upholds systemic racism and disproportionately impacts women.

Feb. 2023 Joined investor letter requesting a dialogue on the company's future strategy on tobacco sales and statements promising transparency regarding the issue.

Feb. 2023 Participated in investor letter to Congress in support of the Department of Labor’s ESG Rule and opposing actions that would take away investor choice.

Aug. 2023 Pharmaceutical companies are filing a lawsuit against the Department of Health and Human Services over the IRA provision allowing the government to negotiate drug prices. Joined investor statement asking the companies and their trade associations to drop the lawsuits.